The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-09-25

AUTHORS

Eunyoung Heo, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee

ABSTRACT

BackgroundDiabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM. Its effect on preventing the development of TB among patients who are newly diagnosed with DM remains unclear.MethodsThis was a retrospective cohort study using the claims database of the Korean Health Insurance Review and Assessment Service. The study population included patients who were newly diagnosed with type 2 DM and who were treated with anti-diabetic drugs between 1 January 2003 and 31 March 2011. A patient was defined as a metformin user if he/she had taken metformin for more than 28 days within 6 months since cohort entry, and as a metformin non-user if he/she had never been treated with metformin. The development of TB within 2 years after the index date was compared by Cox proportional hazard regression models between metformin users and 1:1 propensity score (PS)-matched non-users.ResultsAmong 76,973 patients who were newly diagnosed with type 2 DM, 13,396 were classified as metformin users, 52,736 were classified as metformin non-users, and 10,841 were excluded from the final analysis. PS-matched Cox proportional hazard regression models revealed that metformin use was not associated overall with the prevention of TB development (HR 1.17; 95% CI 0.75–1.83; P = 0.482). There was a trend, however, towards a reduction in the development of TB among patients taking a higher cumulative dose of metformin. Patients who were in the highest quartile (Q4) of cumulative metformin dose had only a 10% risk of developing TB compared to metformin non-users. In contrast, during the early phases of metformin treatment, patients in the second quartile (Q2) of cumulative metformin use had a higher risk of developing TB than patients in the first quartile (Q1).ConclusionsOnly the highest cumulative doses of metformin were protective against the development of TB among patients who were newly diagnosed with type 2 DM; lower cumulative doses of metformin did not appear to reduce the incidence of active TB infection. More... »

PAGES

303

References to SciGraph publications

  • 2018-04-20. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up in EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12890-021-01667-4

    DOI

    http://dx.doi.org/10.1186/s12890-021-01667-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141396548

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34563159


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Databases, Factual", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypoglycemic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Incidence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Metformin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Propensity Score", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proportional Hazards Models", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Republic of Korea", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tuberculosis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Internal Medicine, SNU-SMG Boramae Medical Center, Seoul, Republic of Korea", 
              "id": "http://www.grid.ac/institutes/grid.412479.d", 
              "name": [
                "Department of Internal Medicine, SNU-SMG Boramae Medical Center, Seoul, Republic of Korea"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Heo", 
            "givenName": "Eunyoung", 
            "id": "sg:person.010075641227.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010075641227.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Statistics, Kyungpook National University, Daegu, Republic of Korea", 
              "id": "http://www.grid.ac/institutes/grid.258803.4", 
              "name": [
                "Department of Statistics, Kyungpook National University, Daegu, Republic of Korea"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kim", 
            "givenName": "Eunyoung", 
            "id": "sg:person.0651540207.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651540207.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Information Statistics, Andong National University, Andong, Republic of Korea", 
              "id": "http://www.grid.ac/institutes/grid.252211.7", 
              "name": [
                "Department of Information Statistics, Andong National University, Andong, Republic of Korea"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Jang", 
            "givenName": "Eun Jin", 
            "id": "sg:person.0750142431.78", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750142431.78"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea", 
              "id": "http://www.grid.ac/institutes/grid.412484.f", 
              "name": [
                "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lee", 
            "givenName": "Chang-Hoon", 
            "id": "sg:person.0743464132.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464132.81"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s10096-018-3242-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103487703", 
              "https://doi.org/10.1007/s10096-018-3242-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-09-25", 
        "datePublishedReg": "2021-09-25", 
        "description": "BackgroundDiabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM. Its effect on preventing the development of TB among patients who are newly diagnosed with DM remains unclear.MethodsThis was a retrospective cohort study using the claims database of the Korean Health Insurance Review and Assessment Service. The study population included patients who were newly diagnosed with type 2 DM and who were treated with anti-diabetic drugs between 1 January 2003 and 31 March 2011. A patient was defined as a metformin user if he/she had taken metformin for more than 28\u00a0days within 6\u00a0months since cohort entry, and as a metformin non-user if he/she had never been treated with metformin. The development of TB within 2\u00a0years after the index date was compared by Cox proportional hazard regression models between metformin users and 1:1 propensity score (PS)-matched non-users.ResultsAmong 76,973 patients who were newly diagnosed with type 2 DM, 13,396 were classified as metformin users, 52,736 were classified as metformin non-users, and 10,841 were excluded from the final analysis. PS-matched Cox proportional hazard regression models revealed that metformin use was not associated overall with the prevention of TB development (HR 1.17; 95% CI 0.75\u20131.83; P\u2009=\u20090.482). There was a trend, however, towards a reduction in the development of TB among patients taking a higher cumulative dose of metformin. Patients who were in the highest quartile (Q4) of cumulative metformin dose had only a 10% risk of developing TB compared to metformin non-users. In contrast, during the early phases of metformin treatment, patients in the second quartile (Q2) of cumulative metformin use had a higher risk of developing TB than patients in the first quartile (Q1).ConclusionsOnly the highest cumulative doses of metformin were protective against the development of TB among patients who were newly diagnosed with type 2 DM; lower cumulative doses of metformin did not appear to reduce the incidence of active TB infection.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12890-021-01667-4", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1024955", 
            "issn": [
              "1471-2466"
            ], 
            "name": "BMC Pulmonary Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "21"
          }
        ], 
        "keywords": [
          "development of tuberculosis", 
          "type 2 DM", 
          "Cox proportional hazards regression model", 
          "proportional hazards regression models", 
          "hazards regression models", 
          "metformin users", 
          "anti-diabetic drugs", 
          "metformin use", 
          "cumulative doses", 
          "Korean Health Insurance Review", 
          "type 2 diabetes mellitus", 
          "cumulative metformin dose", 
          "active TB infection", 
          "retrospective cohort study", 
          "high cumulative doses", 
          "high cumulative dose", 
          "Health Insurance Review", 
          "anti-TB effects", 
          "dose-dependent effect", 
          "BackgroundDiabetes mellitus", 
          "cohort entry", 
          "index date", 
          "TB infection", 
          "cohort study", 
          "diabetes mellitus", 
          "regression models", 
          "highest quartile", 
          "metformin treatment", 
          "TB development", 
          "claims database", 
          "metformin dose", 
          "Insurance Review", 
          "cumulative dose", 
          "risk factors", 
          "study population", 
          "high risk", 
          "first quartile", 
          "patients", 
          "second quartile", 
          "metformin", 
          "tuberculosis", 
          "propensity score", 
          "Assessment Service", 
          "final analysis", 
          "quartile", 
          "mellitus", 
          "dose", 
          "doses", 
          "early phase", 
          "drugs", 
          "risk", 
          "DM", 
          "MethodsThis", 
          "ResultsAmong", 
          "infection", 
          "incidence", 
          "ConclusionsOnly", 
          "months", 
          "prevention", 
          "treatment", 
          "scores", 
          "effect", 
          "days", 
          "review", 
          "development", 
          "population", 
          "years", 
          "use", 
          "factors", 
          "database", 
          "study", 
          "contrast", 
          "entry", 
          "date", 
          "reduction", 
          "services", 
          "analysis", 
          "model", 
          "trends", 
          "phase", 
          "users", 
          "PS"
        ], 
        "name": "The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus", 
        "pagination": "303", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141396548"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12890-021-01667-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34563159"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12890-021-01667-4", 
          "https://app.dimensions.ai/details/publication/pub.1141396548"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_913.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12890-021-01667-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12890-021-01667-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12890-021-01667-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12890-021-01667-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12890-021-01667-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    248 TRIPLES      21 PREDICATES      126 URIs      117 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12890-021-01667-4 schema:about N079f6f4ab46448029d01fe2fb94c570e
    2 N07f10dab3480484d95bd7400d1b13951
    3 N1e1191a798fa4bcdbaeed74abc7bc898
    4 N3431e7a5e27948fea7890760a4622208
    5 N3f961faf981944699f5d91bb5245e602
    6 N3ff7b405cf19402781db7d02d7af257a
    7 N43a656f4014741078f6be8d3a276424c
    8 N50e896e734854902a22b1fe83106b7b8
    9 N56d183de21314d878ff599718e14f68d
    10 N7db08d1e557342d5ae6c51b167b84244
    11 N7ecd4f10ddda479eb68f2269151c619a
    12 N9594ad3769f04c9ba76ed576f68a46ba
    13 Na68c986f59d2431d9b6a0d78661ce004
    14 Nb3ae89508586421b9da892b99f2399c3
    15 Nc1509b1123e644358efb87f88de0b116
    16 Nc2b2bcad674646f786501399b86ccde5
    17 Nd7a700cc19134a33a041e58392c9b6ce
    18 Nea1305d86da54240a4f17844d38235ed
    19 anzsrc-for:11
    20 anzsrc-for:1103
    21 schema:author N98f62c172d8740708372674d9069146f
    22 schema:citation sg:pub.10.1007/s10096-018-3242-6
    23 schema:datePublished 2021-09-25
    24 schema:datePublishedReg 2021-09-25
    25 schema:description BackgroundDiabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM. Its effect on preventing the development of TB among patients who are newly diagnosed with DM remains unclear.MethodsThis was a retrospective cohort study using the claims database of the Korean Health Insurance Review and Assessment Service. The study population included patients who were newly diagnosed with type 2 DM and who were treated with anti-diabetic drugs between 1 January 2003 and 31 March 2011. A patient was defined as a metformin user if he/she had taken metformin for more than 28 days within 6 months since cohort entry, and as a metformin non-user if he/she had never been treated with metformin. The development of TB within 2 years after the index date was compared by Cox proportional hazard regression models between metformin users and 1:1 propensity score (PS)-matched non-users.ResultsAmong 76,973 patients who were newly diagnosed with type 2 DM, 13,396 were classified as metformin users, 52,736 were classified as metformin non-users, and 10,841 were excluded from the final analysis. PS-matched Cox proportional hazard regression models revealed that metformin use was not associated overall with the prevention of TB development (HR 1.17; 95% CI 0.75–1.83; P = 0.482). There was a trend, however, towards a reduction in the development of TB among patients taking a higher cumulative dose of metformin. Patients who were in the highest quartile (Q4) of cumulative metformin dose had only a 10% risk of developing TB compared to metformin non-users. In contrast, during the early phases of metformin treatment, patients in the second quartile (Q2) of cumulative metformin use had a higher risk of developing TB than patients in the first quartile (Q1).ConclusionsOnly the highest cumulative doses of metformin were protective against the development of TB among patients who were newly diagnosed with type 2 DM; lower cumulative doses of metformin did not appear to reduce the incidence of active TB infection.
    26 schema:genre article
    27 schema:isAccessibleForFree true
    28 schema:isPartOf N157d6a63631847f5939c10a9aa2e6c94
    29 Nfd10040c39ac4ee28fc35e09df9bfa2d
    30 sg:journal.1024955
    31 schema:keywords Assessment Service
    32 BackgroundDiabetes mellitus
    33 ConclusionsOnly
    34 Cox proportional hazards regression model
    35 DM
    36 Health Insurance Review
    37 Insurance Review
    38 Korean Health Insurance Review
    39 MethodsThis
    40 PS
    41 ResultsAmong
    42 TB development
    43 TB infection
    44 active TB infection
    45 analysis
    46 anti-TB effects
    47 anti-diabetic drugs
    48 claims database
    49 cohort entry
    50 cohort study
    51 contrast
    52 cumulative dose
    53 cumulative doses
    54 cumulative metformin dose
    55 database
    56 date
    57 days
    58 development
    59 development of tuberculosis
    60 diabetes mellitus
    61 dose
    62 dose-dependent effect
    63 doses
    64 drugs
    65 early phase
    66 effect
    67 entry
    68 factors
    69 final analysis
    70 first quartile
    71 hazards regression models
    72 high cumulative dose
    73 high cumulative doses
    74 high risk
    75 highest quartile
    76 incidence
    77 index date
    78 infection
    79 mellitus
    80 metformin
    81 metformin dose
    82 metformin treatment
    83 metformin use
    84 metformin users
    85 model
    86 months
    87 patients
    88 phase
    89 population
    90 prevention
    91 propensity score
    92 proportional hazards regression models
    93 quartile
    94 reduction
    95 regression models
    96 retrospective cohort study
    97 review
    98 risk
    99 risk factors
    100 scores
    101 second quartile
    102 services
    103 study
    104 study population
    105 treatment
    106 trends
    107 tuberculosis
    108 type 2 DM
    109 type 2 diabetes mellitus
    110 use
    111 users
    112 years
    113 schema:name The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus
    114 schema:pagination 303
    115 schema:productId N00a0c33cea554df79ad3ed39096f10c0
    116 N312fd5d1f03742b8acc74d17498ba974
    117 Nd3806b23adc84f1f8141df742e11041c
    118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141396548
    119 https://doi.org/10.1186/s12890-021-01667-4
    120 schema:sdDatePublished 2022-09-02T16:07
    121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    122 schema:sdPublisher N9d69b4a0b195403e9e1ca0282164b200
    123 schema:url https://doi.org/10.1186/s12890-021-01667-4
    124 sgo:license sg:explorer/license/
    125 sgo:sdDataset articles
    126 rdf:type schema:ScholarlyArticle
    127 N00a0c33cea554df79ad3ed39096f10c0 schema:name pubmed_id
    128 schema:value 34563159
    129 rdf:type schema:PropertyValue
    130 N079f6f4ab46448029d01fe2fb94c570e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Republic of Korea
    132 rdf:type schema:DefinedTerm
    133 N07f10dab3480484d95bd7400d1b13951 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Adult
    135 rdf:type schema:DefinedTerm
    136 N157d6a63631847f5939c10a9aa2e6c94 schema:issueNumber 1
    137 rdf:type schema:PublicationIssue
    138 N1e1191a798fa4bcdbaeed74abc7bc898 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Diabetes Mellitus, Type 2
    140 rdf:type schema:DefinedTerm
    141 N312fd5d1f03742b8acc74d17498ba974 schema:name dimensions_id
    142 schema:value pub.1141396548
    143 rdf:type schema:PropertyValue
    144 N3431e7a5e27948fea7890760a4622208 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Risk Factors
    146 rdf:type schema:DefinedTerm
    147 N3f961faf981944699f5d91bb5245e602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Proportional Hazards Models
    149 rdf:type schema:DefinedTerm
    150 N3ff7b405cf19402781db7d02d7af257a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Humans
    152 rdf:type schema:DefinedTerm
    153 N43a656f4014741078f6be8d3a276424c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Dose-Response Relationship, Drug
    155 rdf:type schema:DefinedTerm
    156 N50e896e734854902a22b1fe83106b7b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Female
    158 rdf:type schema:DefinedTerm
    159 N56d183de21314d878ff599718e14f68d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Propensity Score
    161 rdf:type schema:DefinedTerm
    162 N6aa1ef214c094a4a8c7ea81d4faa24ef rdf:first sg:person.0743464132.81
    163 rdf:rest rdf:nil
    164 N7db08d1e557342d5ae6c51b167b84244 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Incidence
    166 rdf:type schema:DefinedTerm
    167 N7ecd4f10ddda479eb68f2269151c619a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Hypoglycemic Agents
    169 rdf:type schema:DefinedTerm
    170 N9594ad3769f04c9ba76ed576f68a46ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Male
    172 rdf:type schema:DefinedTerm
    173 N98f62c172d8740708372674d9069146f rdf:first sg:person.010075641227.89
    174 rdf:rest Nbcfb6ebcc94b4e6a8b6b3db82af5959b
    175 N9d69b4a0b195403e9e1ca0282164b200 schema:name Springer Nature - SN SciGraph project
    176 rdf:type schema:Organization
    177 Na68c986f59d2431d9b6a0d78661ce004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Retrospective Studies
    179 rdf:type schema:DefinedTerm
    180 Nb3ae89508586421b9da892b99f2399c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Metformin
    182 rdf:type schema:DefinedTerm
    183 Nbcfb6ebcc94b4e6a8b6b3db82af5959b rdf:first sg:person.0651540207.07
    184 rdf:rest Ne54069155cca4370a4b489594ffa70c7
    185 Nc1509b1123e644358efb87f88de0b116 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Tuberculosis
    187 rdf:type schema:DefinedTerm
    188 Nc2b2bcad674646f786501399b86ccde5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Middle Aged
    190 rdf:type schema:DefinedTerm
    191 Nd3806b23adc84f1f8141df742e11041c schema:name doi
    192 schema:value 10.1186/s12890-021-01667-4
    193 rdf:type schema:PropertyValue
    194 Nd7a700cc19134a33a041e58392c9b6ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Databases, Factual
    196 rdf:type schema:DefinedTerm
    197 Ne54069155cca4370a4b489594ffa70c7 rdf:first sg:person.0750142431.78
    198 rdf:rest N6aa1ef214c094a4a8c7ea81d4faa24ef
    199 Nea1305d86da54240a4f17844d38235ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Aged
    201 rdf:type schema:DefinedTerm
    202 Nfd10040c39ac4ee28fc35e09df9bfa2d schema:volumeNumber 21
    203 rdf:type schema:PublicationVolume
    204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    205 schema:name Medical and Health Sciences
    206 rdf:type schema:DefinedTerm
    207 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    208 schema:name Clinical Sciences
    209 rdf:type schema:DefinedTerm
    210 sg:journal.1024955 schema:issn 1471-2466
    211 schema:name BMC Pulmonary Medicine
    212 schema:publisher Springer Nature
    213 rdf:type schema:Periodical
    214 sg:person.010075641227.89 schema:affiliation grid-institutes:grid.412479.d
    215 schema:familyName Heo
    216 schema:givenName Eunyoung
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010075641227.89
    218 rdf:type schema:Person
    219 sg:person.0651540207.07 schema:affiliation grid-institutes:grid.258803.4
    220 schema:familyName Kim
    221 schema:givenName Eunyoung
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651540207.07
    223 rdf:type schema:Person
    224 sg:person.0743464132.81 schema:affiliation grid-institutes:grid.412484.f
    225 schema:familyName Lee
    226 schema:givenName Chang-Hoon
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464132.81
    228 rdf:type schema:Person
    229 sg:person.0750142431.78 schema:affiliation grid-institutes:grid.252211.7
    230 schema:familyName Jang
    231 schema:givenName Eun Jin
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750142431.78
    233 rdf:type schema:Person
    234 sg:pub.10.1007/s10096-018-3242-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103487703
    235 https://doi.org/10.1007/s10096-018-3242-6
    236 rdf:type schema:CreativeWork
    237 grid-institutes:grid.252211.7 schema:alternateName Department of Information Statistics, Andong National University, Andong, Republic of Korea
    238 schema:name Department of Information Statistics, Andong National University, Andong, Republic of Korea
    239 rdf:type schema:Organization
    240 grid-institutes:grid.258803.4 schema:alternateName Department of Statistics, Kyungpook National University, Daegu, Republic of Korea
    241 schema:name Department of Statistics, Kyungpook National University, Daegu, Republic of Korea
    242 rdf:type schema:Organization
    243 grid-institutes:grid.412479.d schema:alternateName Department of Internal Medicine, SNU-SMG Boramae Medical Center, Seoul, Republic of Korea
    244 schema:name Department of Internal Medicine, SNU-SMG Boramae Medical Center, Seoul, Republic of Korea
    245 rdf:type schema:Organization
    246 grid-institutes:grid.412484.f schema:alternateName Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    247 schema:name Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    248 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...